Search Videos and More
News
Cracking the Code
It was 2014 and Filbin was a hematology/oncology fellow specializing in pediatric brain cancer. Her mentor, David Williams, MD, now associate chair of Pediatric Oncology at Dana-Farber, wanted her to go to a lab at the Massachusetts Institute of Technology (MIT) for the research portion of her fellowship.
News
New Diagnostic Tool Developed at Dana-Farber Revolutionizes Acute Leukemia Diagnosis
Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated.
Document
AACR Pediatric Special Conference in Cancer Research
September 25 - 28, 2025, Boston, MA
News
Dana-Farber Research News 09.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 16 - August 31.
News
Dana-Farber Treats First Patient with Approved Gene Therapy for Beta Thalassemia
A few years ago, Oscar Diep, a 33-year-old software engineer living in Weymouth, Mass., started needing blood transfusions more often to manage a blood disorder called beta thalassemia.
News
Dana-Farber Research News 09.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 - August 15.
News
Clinical Trials and Research for Mantle Cell Lymphoma
Dana-Farber Cancer Institute is at the forefront of research in mantle cell lymphoma. We seek to advance more effective treatment options and reduce treatment side effects for patients with mantle cell lymphoma.
Course
Stem Cell Transplant and Cellular Therapies Symposium 2025
Enhance your ability to manage capacity effectively by gaining essential knowledge and strategies to streamline care and improve outcomes for patients undergoing stem cell transplants or CAR T-cell therapies.
News
New Research Sheds Light on Why Tamoxifen May Lead to Higher Risk of Uterine Cancer
Since its introduction in the 1970s, tamoxifen has significantly improved survival rates for millions of patients with estrogen receptor–positive breast cancer.
News
Dana-Farber Researchers Find Less Treatment May be More in Mantle Cell Lymphoma
For a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back.
News
Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark
Breast cancer patients who participated in a remote weight loss intervention program lost an average of 4.7 percent of their baseline body weight after one year, while those in the education only control group gained an average 1 percent of their baseline weight, according to a new report from Dana-Farber Cancer Institute investigators.
News
New Strategy for Small Cell Lung Cancer Treatment Emerges from Dana-Farber Science
Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.